Navigation Links
Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
Date:5/9/2008

nactive status) certified public accountant in the state of California and is a member of the American Institute of Certified Public Accountants and the Association of Bioscience Financial Officers.

Recent Accomplishments

In the first quarter of 2008, we continued to progress our development pipeline in all three therapeutic areas of focus, including:

-- Announced positive preliminary results for RDEA806, our lead non-

nucleoside reverse transcriptase inhibitor (NNRTI), in a Phase 2a

monotherapy study in patients with human-immunodeficiency virus (HIV),

demonstrating an up to 2.0 log placebo-adjusted reduction in plasma

viral load after seven days of treatment;

-- Completed a first-in-human micro-dosing study of our second generation

NNRTI, RDEA427, and selected it as a development candidate;

-- Completed a first-in-human micro-dosing study of our second generation

MEK inhibitor, RDEA436, and selected it as a development candidate;

-- Presented preclinical data demonstrating potent activity and favorable

resistance profiles for our next generation NNRTI family of compounds

against HIV at the 15th Annual Conference on Retroviruses and

Opportunistic Infections (CROI) and the 21st International Conference

on Antiviral Research (ICAR);

-- Presented preclinical data demonstrating the potent activity and

favorable pharmacokinetic profile of our mitogen-activated ERK kinase

(MEK) inhibitor family of compounds in the treatment of cancer,

preliminary Phase 1 data demonstrating the potential for once-daily

oral dosing of RDEA119, our lead MEK inhibitor, and first-in-human

micro-dose data for RDEA436, at the American Association for Cancer

Research (AACR);

-- Established two scientific advisory boards to guide the HIV and

inflammation programs; and

-- Relocated ou
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
10. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
11. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2010)... China , March 18 /PRNewswire-Asia-FirstCall/ -- ... or "the Company") (Nasdaq: CSKI ), a,leading ... the People,s Republic of China ("PRC"), today ... co-developed by Taiwan,Golden Biotechnology Corporation ("Golden Biotech") was ...
(Date:3/17/2010)... company products from its distribution operations in Enfield, Connecticut on Sunday, March 14 .   , ... , , ... ... Lilly is working with the U.S. ...
(Date:3/17/2010)... On March 17, 2010 the FDA gave approval to ... hearing restoration device. The approval follows a December 18, 2009 ... in favor of approving the Esteem® for moderate to severe sensorineural ... they believe the Esteem® "represents a breakthrough technology." , ...
Breaking Medicine Technology:China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology 2China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology 3China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology 4China Sky One Medical Announces Antroquinonol Capsule Recognized as Breakthrough Drug by Chinese Ministry of Science and Technology 5Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 2Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 3Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 4Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 5Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 6Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 7Statement From Eli Lilly and Company Regarding Stolen Company Products From Enfield, Connecticut Distribution Operations 8FDA Approves First of Its Kind, Fully Implantable (Surgically), Invisible, Prosthetic Hearing Restoration Device 2The Sports Club LA and Reebok Sports Club NY Team Up With LinkedIn to Host a Series of Networking Events Strengthening Career and Well Being 47951 1The Sports Club LA and Reebok Sports Club NY Team Up With LinkedIn to Host a Series of Networking Events Strengthening Career and Well Being 47951 2The Sports Club LA and Reebok Sports Club NY Team Up With LinkedIn to Host a Series of Networking Events Strengthening Career and Well Being 47951 3The Sports Club LA and Reebok Sports Club NY Team Up With LinkedIn to Host a Series of Networking Events Strengthening Career and Well Being 47951 4HealthMetrix Research Selects Medicare Advantage Plan Websites for 2009 MedicareWebWatch Certification 47946 1HealthMetrix Research Selects Medicare Advantage Plan Websites for 2009 MedicareWebWatch Certification 47946 2Ohios Childrens Hospitals Release New Results of Collaboration Aimed at Saving Childrens Lives 47941 1Ohios Childrens Hospitals Release New Results of Collaboration Aimed at Saving Childrens Lives 47941 2Ohios Childrens Hospitals Release New Results of Collaboration Aimed at Saving Childrens Lives 47941 3
... A. Grant, MD,Retina Macular Care, presented the ... that was designed to evaluate the adjuvant,use ... Lucentis(R),(ranibizumab) treatment of choroidal neovascularization secondary to,age-related ... presentation at,the 2008 Annual Meeting of the ...
... Italy, April 26 Bristol-Myers Squibb,Company (NYSE: ... E.A.R.L.Y. study,(ETV-079), in which treatment of antiviral-naive adult ... greater long-term viral,load reduction than adefovir at 96 ... Suppression of viral load to undetectable,levels is a ...
Other Medicine Technology:Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 2Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 3Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) 4BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 2BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 3BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 4BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 5BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 6BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients 7
(Date:3/21/2010)... are big winners in the comprehensive healthcare reform package that the House is expected to approve today, according to Congressman Chaka Fattah ... ... ... ... ...
(Date:3/18/2010)... ... events – it can actually take a toll on health, according to a new study ... ... impact the way people perceive negative events – it can actually take a toll on ...
(Date:3/18/2010)... , ... , ... ... WASHINGTON , March 18 Kids in Michigan will take center stage in the fight against tobacco on ...
(Date:3/18/2010)... State Leaders Urged to Support Higher Tobacco Taxes, Other Tobacco Prevention Initiatives , ... , , ... ... WASHINGTON , March 18 ...
(Date:3/18/2010)... Legacy(SM) , ... ... WASHINGTON , March 18 The ... , ...
Breaking Medicine News(10 mins):Health News:Rep. Fattah Says Small Businesses in Philadelphia Are Big Winners in Today's Healthcare Reform 2Health News:Rep. Fattah Says Small Businesses in Philadelphia Are Big Winners in Today's Healthcare Reform 3Health News:Low Self-Esteem Can Threaten Health, Online Dating Study Finds 2Health News:Low Self-Esteem Can Threaten Health, Online Dating Study Finds 3Health News:Michigan Kids 'Kick Butts' on March 24 2Health News:Michigan Kids 'Kick Butts' on March 24 3Health News:Michigan Kids 'Kick Butts' on March 24 4Health News:Michigan Kids 'Kick Butts' on March 24 5Health News:Missouri Kids 'Kick Butts' on March 24 2Health News:Missouri Kids 'Kick Butts' on March 24 3Health News:Missouri Kids 'Kick Butts' on March 24 4Health News:Missouri Kids 'Kick Butts' on March 24 5Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 2Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 3Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 4Health News:Food and Drug Administration Issues Final Rule Regarding Sale, Distribution, and Use of Cigarettes and Smokeless Tobacco 5
... Hologic, Inc. (Nasdaq: HOLX ) today ... at the 8th Annual Needham Life Sciences Conference in ... p.m. (Eastern) and the Jefferies 3rd Annual Healthcare Conference ... 4:15 p.m. (Eastern).Interested parties are invited to listen to ...
... May 20 The National Osteoporosis Foundation (NOF) will ... Field; local D.C. celebrities and owners of FLEET FEET ... of EmpowHer, Michelle King Robson, at its Silver ... in Washington, D.C. Janet Hubert, entrepreneur and star of ...
... the accomplishments of medical education professionals in Texas. , ... ... national financial services group and the leading provider of retirement services ... it is soliciting statewide nominations for the 2009 TIAA-CREF Distinguished ...
... Years After Institute of Medicine Found Up To 98,000 Die ... the Institute of Medicine (IOM) sounded the alarm about the ... "To Err is Human." The report prompted a rush ... the decade since the report was published, little progress has ...
... CHARLOTTE, N.C., May 20 MedCath Corporation (Nasdaq: MDTH ) will host ... from its second quarter ended March 31, 2009. The company will issue a press ... Commission prior to the earnings call. , ... When: ...
... VSCP ), a leading provider of quantitative ... received notification from The NASDAQ Stock Market that it ... bid price requirement, and further, that it currently complies ... regain compliance with the bid price rule, the Company ...
Other Medicine News:Health News:Sally Field, Phil and Jan Fenty, and Michelle King Robson to Be Honored at Benefit for Osteoporosis and Bone Health Awareness 2Health News:Sally Field, Phil and Jan Fenty, and Michelle King Robson to Be Honored at Benefit for Osteoporosis and Bone Health Awareness 3Health News:Sally Field, Phil and Jan Fenty, and Michelle King Robson to Be Honored at Benefit for Osteoporosis and Bone Health Awareness 4Health News:Open Call for Nominations for the Sixth Annual TIAA-CREF Distinguished Medical Educator Award 2Health News:Open Call for Nominations for the Sixth Annual TIAA-CREF Distinguished Medical Educator Award 3Health News:Open Call for Nominations for the Sixth Annual TIAA-CREF Distinguished Medical Educator Award 4Health News:U.S. Health Care System Fails to Protect Patients From Deadly Medical Errors 2Health News:U.S. Health Care System Fails to Protect Patients From Deadly Medical Errors 3Health News:U.S. Health Care System Fails to Protect Patients From Deadly Medical Errors 4Health News:U.S. Health Care System Fails to Protect Patients From Deadly Medical Errors 5Health News:MedCath Corporation to Hold Conference Call on Second Quarter Results 2Health News:VirtualScopics Regains NASDAQ Compliance 2
Inquire...
Inquire...
... In operation and optical performance, the SZX7 ... working comfort in every task, from routine ... one of the best zoom ratios in ... clarity, true color and accurate reproduction of ...
The Stereomicroscope Stemi 2000 meets your demands in two respects. On the one hand it offers the low-price advantage common with Greenough-type instruments, on the other hand it features superior pe...
Medicine Products: